Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. [electronic resource]
Producer: 20201228Description: 37-51 p. digitalISSN:- 1750-7448
- Antineoplastic Agents, Immunological -- therapeutic use
- Antineoplastic Protocols
- Carcinoma, Renal Cell -- drug therapy
- Computer Simulation
- Cost-Benefit Analysis
- Drug Therapy, Combination
- Humans
- Ipilimumab -- therapeutic use
- Kidney Neoplasms -- drug therapy
- Models, Economic
- Neoplasm Staging
- Nivolumab -- therapeutic use
- Quality-Adjusted Life Years
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.